Key Points - Rosen Law Firm reminds Capricor Therapeutics, Inc. investors of lead plaintiff deadline on September 28, 2026 - Capricor securities purchasers between December 17, 2025, and July 26, 2026 may be entitled to compensation - Lawsuits allege material misstatements regarding lead product candidates and FDA compliance - Investors urged to contact Kessler Topaz...
Scienjoy Holding Corporation (SJ) - This analysis reviews how the stock price reacted after the last...
Tuniu Corporation (TOUR) - This analysis reviews how the stock price reacted after the last 12...
StealthGas Inc. (GASS) - This analysis reviews how the stock price reacted after the last 12...
SelectQuote, Inc. (SLQT) - This analysis reviews how the stock price reacted after the last 12...
from Craig-Hallum issued a price target of $16.25 for PSNL on 2026-08-24 12:55:17.The adjusted price target was set to $16.25.At the time of the announcement, PSNL was trading at $17.22.The...
from Barrington issued a price target of $14.00 for VMD on 2026-08-24 11:33:30.The adjusted price target was set to $14.00.At the time of the announcement, VMD was trading at $8.85.VMD...
Martin Auster from Raymond James issued a price target of $18.00 for STTK on 2026-08-24 10:06:00.The adjusted price target was set to $18.00.At the time of the announcement, STTK was...
from Goldman Sachs issued a price target of $20.00 for AEVA on 2026-08-24 00:20:28.The adjusted price target was set to $20.00.At the time of the announcement, AEVA was trading at...
Danielle Brill from Truist Financial issued a price target of $20.00 for SLDB on 2026-08-21 11:27:42.The adjusted price target was set to $20.00.At the time of the announcement, SLDB was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
